Shumei Kato

28PUBLICATIONS
110CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cheminformatics and quantitative structure-activity relationshipsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|May 25, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.

|May 05, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.

|Feb 07, 2026
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

Tadashi Manabe, Hannah C Bergo, Qingtian Li

|Jan 08, 2026
Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.

Jason K Sicklick, Daisuke Nishizaki, Hirotaka Miyashita

|Nov 24, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.

Tadashi Manabe, Hannah C Bergo, Qingtian Li

|Jul 23, 2025
Personalized N-of-1 Combination Therapies for Advanced Gastrointestinal Stromal Tumors.

Sangkyu Noh, Ashwyn K Sharma, Paul T Fanta

Pageof 5

Frequent Collaborators

16 joint publications

Razelle Kurzrock

9 joint publications

Jason Sicklick

7 joint publications

Ryosuke Okamura

4 joint publications

Daisuke Nishizaki